LIFE SCIENCES
Accelerate & Simplify Your Research
Innovative and Open RUO* solutions to fully automatize your Cell-Mediated Immune response.
*RUO: Research Use Only
Disclaimer: Product availability varies by country. Please consult your local bioMérieux representative for product availability in your country.
- LIFE SCIENCES SOLUTIONS
- LIFE SCIENCES SOLUTIONS
- Overview
- Products
- Resources
Overview
Cell-Mediated Immunity (CMI)
Better understanding T-cell immune response to have a comprehensive picture of immune status has become a growing need. CMI provides complementary information to humoral immunity.
In addition, emergence of novel therapies (CAR-T cell therapy, immunotherapy..) over the last decade has demonstrated the pivotal role of T-cells in some conditions. Therefore, exploring cellular immunity has become crucial.
What are the Current Challenges?
Current testing tools are very cumbersome, and it hinders their broad usage in routine research.
IGRA in healthy volunteers and in patients admitted in Intensive Care Unit with septic shock during 1 week
References
1. Rahimi et al. Cytokine, 2023
Automatize Your Cell-Mediated Immune Response to Simplify and Accelerate Your Research While Ensuring Standardization
A fully automated Interferon-Y Release Assay (IGRA) to monitor Cell-Mediated Immunity in 4 hours may differentiate healthy volunteers from septic shock patients with impaired cellular functionality1.
Products
VIDAS® IGRA RUO* SOLUTIONS
First fully automated functional assays for CMI assessment
All steps managed inside the VIDAS® 3 from a single whole blood tube.1
bioMérieux VIDAS® 3
Research Tools
Thanks to this internal know-how, bioMérieux designed a range of open IGRA RUO solutions (IGRA RUO assays and stimulants) to customize research on Cell-Mediated Immunity response. These solutions are fully automated on VIDAS® 3 instruments.
Thanks to this open concept, it is also possible to use your homemade stimulants or stimulants from a third party.
OPEN IGRA RUO ASSAYS
To automatize your clinical research
VIDAS® IGRA 4 RUO: Assess cellular immune status in various clinical conditions / VIDAS® IGRA 16 RUO: Explore specific cellular immunity with the antigen of your choice
- On-board incubation in 3.5 or 16 hours according to the stimulant chosen, then automatic reading
- Less than 5 min technician time
- These assays have been developed to limit the risk of error, variability due to PBMC extraction
- Research areas: Transplant, Vaccination, Infection, Immunotherapy...
STIMULANTS
VIDAS® STIMM™ FAMILY
bioMérieux is also developing a range of stimulants for your research. These stimulants have been optimized for immunocompromised patients.
- VIDAS® STIMM™ T RUO: Immune status assessment in only 4 hours
- VIDAS® STIMM™ CMV RUO: CMV lysate for specific cellular response
- VIDAS® STIMM™ BASIC RUO: to perform Open IGRA RUO assays in semi-automated mode
- STIMULANTS OF YOUR CHOICE (homemade or 3rd party)
INSTRUMENTS
VIDAS® 3
To perform your functional assays in a fully automated mode. All steps are done on board by the VIDAS® 3: pipetting, stimulation, incubation, read-out.
VIDAS® KUBE™
To run your cytokine assays: VIDAS® IL6 RUO, VIDAS® IFNg RUO.
BRING YOUR RESEARCH INTO A NEW ERA
| FULLY AUTOMATED ASSAYS CMI response | |
| Product Name | Reference |
|---|---|
| OPEN IGRA RUO | |
| VIDAS® IGRA 4 RUO | 424329 |
| VIDAS® IGRA 16 RUO | 424328 |
| STIMULANTS | |
| VIDAS® COVID STIMM RUO | 424330 |
| VIDAS® STIMM™ T RUO | 424331 |
| VIDAS® STIMM™ CMV RUO | 424616 |
| VIDAS® STIMM™ BASIC RUO | 424615 |
| ADDITIONAL ASSAYS | |
| Product Name | Reference |
|---|---|
| CYTOKINES | |
| VIDAS® IFNg RUO | 423304 |
| VIDAS® IL-6 RUO | 423305 |
BECAUSE IT MAKES SENSE ON VIDAS®
REFERENCES
1Mouton et al. Eut J. Immunol, 2021
*RUO: Research Use Only
Resources
Publications:
Specific detection of memory T cells in COVID-19 patients using standardized whole-blood IGRA
bioMérieux & al. Eur J. Immunol, Sept 2021
Immunogenicity and efficacy of heterologousChad0x1/BNT162b2 vaccination
Pozzeto B, Trouillet Assant S & al. Nature, Oct 2021
The polarity and specificity of antiviral T lymphocyte responses determine susceptibility to SARS-CoV-2 infection in patients with cancer and healthy individuals
Fahrner J-E, Zitvogel L & al. Cancer Discovery, April 2022
Lack of Sars-CoV-2 – specific cellular response in critically ill COVID-19 patients despite apparent effective vaccination.
Bidar F, Monneret G, Berthier F, Lukaszewicz AC, Venet F. Critical Care, June 2022
Enhancement of pre-existing immunity during breakthrough infections Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection
C. Saade and al. Emerg Microbed Infect. Dec 2022
Fully automated interferon-γ release assay to monitor antigen-independent T cell functionality: A proof of concept study in septic shock
Cytokine, 2023 Sep:169:156263. doi: 10.1016/j.cyto.2023.156263. Epub 2023 Jun 19.
Adverse outcomes and an immunosuppressed endotype in septic patients with reduced IFN-γ ELISpot
Evan L. Barrios, Monty B. Mazer, and al. JCI Insight, 2024
